BRIEF—Riemser strengthens international profile with new products in Canada and the UK

With the approval of triamcinolone hexacetonide in Canada and the acquisition of distribution rights for Jylamvo (methotrexate) in the UK from Therakind, Germany’s Riemser Pharma is pressing ahead with its internationalization efforts.

Approval of the active substance triamcinolone hexacetonide in Canada was completed in the shortest possible time of within just one year.

As a result, it is closing a supply gap for patients in Canada who suffer from juvenile arthritis. Riemser already markets the active ingredient in 17 countries in Europe, Asia and South America under various trade names. In Germany, the drug is available under the name Lederlon.

In the UK, the company has also acquired the distribution rights for Jylamvo for the English and Irish markets.

Jylamvo facilitates the treatment of rheumatoid arthritis in children as well as in adults because it is taken in liquid form. In addition, it is significantly cheaper than injections.

With both milestones, Riemser sharpens its image as a focused supplier for specialty pharmaceuticals in therapeutic niches in the field of human medicine.